Strs Ohio Acquires 7,870 Shares of Zoetis Inc. $ZTS

Strs Ohio raised its holdings in Zoetis Inc. (NYSE:ZTS) by 5.7% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 146,899 shares of the company’s stock after buying an additional 7,870 shares during the quarter. Strs Ohio’s holdings in Zoetis were worth $22,909,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Vanguard Group Inc. grew its position in shares of Zoetis by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company’s stock worth $6,842,222,000 after buying an additional 189,287 shares during the last quarter. Polen Capital Management LLC lifted its stake in shares of Zoetis by 17.6% in the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after purchasing an additional 1,313,653 shares during the period. Northern Trust Corp lifted its stake in shares of Zoetis by 1.2% in the 1st quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock valued at $1,071,032,000 after purchasing an additional 78,508 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Zoetis by 2.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock valued at $847,293,000 after purchasing an additional 109,791 shares during the period. Finally, Brown Advisory Inc. lifted its stake in shares of Zoetis by 7.6% in the 1st quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company’s stock valued at $725,866,000 after purchasing an additional 312,746 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Up 0.1%

Shares of NYSE:ZTS opened at $144.25 on Friday. The stock has a fifty day simple moving average of $147.15 and a two-hundred day simple moving average of $153.36. The stock has a market capitalization of $63.93 billion, a price-to-earnings ratio of 24.83, a PEG ratio of 2.31 and a beta of 0.90. Zoetis Inc. has a 12-month low of $139.34 and a 12-month high of $183.11. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. The business had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be paid a $0.50 dividend. The ex-dividend date is Friday, October 31st. This represents a $2.00 annualized dividend and a dividend yield of 1.4%. Zoetis’s payout ratio is currently 34.42%.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. Leerink Partnrs cut Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. UBS Group lowered their target price on Zoetis from $165.00 to $158.00 and set a “neutral” rating for the company in a research note on Monday, October 20th. Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Finally, Piper Sandler lifted their price objective on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Four research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $195.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.